ALTRENO LOTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

TRETINOIN

Dostupné s:

BAUSCH HEALTH, CANADA INC.

ATC kód:

D10AD01

INN (Mezinárodní Name):

TRETINOIN

Dávkování:

0.05%

Léková forma:

LOTION

Složení:

TRETINOIN 0.05%

Podání:

TOPICAL

Jednotky v balení:

100

Druh předpisu:

Prescription

Terapeutické oblasti:

CELL STIMULANTS AND PROLIFERANTS

Přehled produktů:

Active ingredient group (AIG) number: 0112395001; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2021-10-08

Charakteristika produktu

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALTRENO
TM
Tretinoin Lotion
Lotion with moisturizers 0.05% w/w
COMEDOLYTIC AGENT
BAUSCH HEALTH, CANADA INC.
2150 St-Elzear Blvd., West
Laval, Quebec H7L 4A8
Canada
DATE OF REVISION:
October 7, 2021
Submission Control No: 251922
_ _
_Pr_
_ALTRENO_
_TM_
_ – Product Monograph Page 2 of 28_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics............................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................
4
4.2
Recommended Dose and Dosage Adjustment
.................................................... 4
4.4
Administration.....................................................................................................
5
5
OVERDOSAGE
...........................................................................................................
5
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
........................ 6
7
WARNINGS AND PRECAUTIONS
..............................................................................
6
7.1
Special Populations
............................................................................................
7
7.1.1
Pregnant Women
...............................................................................